iCamuno Biotherapeutics completes over RMB 100 million Series A3 financing to accelerate AI-driven iPSC cell therapy and organoid platform advancement

Recently, iCamuno Biotherapeutics announced the completion of its Series A3 financing round exceeding RMB 100 million. This financing round was jointly led by Voyagers Capital and InnoVision Capital, with continued investment from New Alliance Capital. Leveraging its proprietary AI-driven predictive modeling system, iCamuno has established a systematic iPSC-based drug development pathway, covering innovative directions including neurological disorders such as Parkinson's disease and epilepsy. The proceeds from this round will be primarily used to accelerate the advancement of multiple allogeneic universal iPSC-derived cell therapies, developed through its AI-driven R&D system, into clinical stages. 

The funding will also support the strategic expansion of iCamuno's two core technology platforms—iPSC-based cell therapy and iPSC-based organoids—providing resources for the clinical advancement of lead programs and marking a critical validation phase for iCamuno's AI-driven cell therapy and drug screening platform development model.

Globally, iPSC-based cell therapies are accelerating their transition from experimental research to industrialization. In February 2026, Japan's Ministry of Health, Labour and Welfare granted conditional approval for two iPSC-derived regenerative medicine products, indicated for severe heart failure and Parkinson's disease respectively, marking the world's first regulatory approvals for iPSC-derived cell products. This milestone not only validates the clinical potential of iPSC technology in terms of safety and feasibility, but also signifies that reprogramming technology, after two decades of development, has officially entered the stage of large-scale clinical application.

Artificial intelligence has become the core driver of iCamuno's platform strategy. Through years of systematic technological accumulation, iCamuno has developed a proprietary AI-driven R&D platform that deeply integrates algorithmic models with experimental data, spanning critical stages including cellular reprogramming, directed differentiation pathway optimization, and quality control. This platform not only significantly enhances R&D efficiency and decision-making precision, but also establishes a continuously iteratable underlying capability framework. This positions iCamuno with a leading systematic R&D capability in the field of AI-enabled iPSC cellular engineering, providing broad development space for rapid expansion across multiple indications and continuous product advancement, while unlocking the industrial potential of iPSC technology in clinical translation and large-scale application.

As an innovative biotechnology company focused on iPSC technology translation, iCamuno has built a foundational capability for low-immunogenicity, universal cells through its proprietary next-generation reprogramming technology and precise multi-gene editing technology. iCamuno's product portfolio addresses major unmet clinical needs, particularly in neurological disorders. Currently, iPSC-derived dopaminergic precursor cells have achieved positive IIT clinical results in Parkinson's disease treatment, while multiple products targeting indications such as epilepsy have entered the IND application stage, continuously advancing universal iPSC-based cell therapies from R&D toward clinical application.

Concurrently, iCamuno has established an autonomous AI plus iPSC organoid platform. This platform focuses on disease modeling and drug development and validation, constructing highly consistent cellular and organoid systems to enable elucidation of complex disease mechanisms, evaluation of candidate targets, and functional validation of novel therapies. By establishing multidimensional phenotypic and molecular data systems, iCamuno is progressively building an organoid model network capable of high-throughput evaluation and precise prediction.

In terms of global expansion, iCamuno has established innovation R&D and clinical centers in Melbourne, Australia, R&D centers in Shanghai and Hangzhou, China, and a GMP manufacturing facility in Suzhou, forming a complete industrial chain spanning R&D, clinical translation, and large-scale production. iCamuno has also established collaborations with international clinical institutions including Massachusetts General Hospital, affiliated with Harvard Medical School, advancing cutting-edge clinical research and translational exploration. Leveraging established international registration pathways and cross-regional collaborative capabilities, iCamuno is laying a solid foundation for the global advancement of its universal iPSC-based cell therapies and organoid platform.